Skip to content
Screener

Intellia Therapeutics NTLA Other Income (Expense)

Other Income (Expense) at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$987K+868%
ALN
Alnylam PharmaceuticalsALNY
-$53.64M-180%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$8.16M-39.8%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$12.9M+17.7%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
$3.21M+5.7%
Prime Medicine logo
Prime MedicinePRME
$1.18M+49.6%

Other financials

Income statement

See full
Revenue$7.7M-46.2%
Operating income-$112.8M-2.5%
Net income-$106.6M-5.3%
EPS (diluted)-$0.80+18.4%

Balance sheet

See full
Cash & equivalents$106.1M-32.0%
Total debt$73.4M-28.4%
Total equity$727.7M+202%
Total assets$857.2M-4.6%

Cash flow

See full
Operating cash flow-$83.1M+16.6%
CapEx$1.8M+657%
Free cash flow-$84.9M+15.0%

Valuation

See full
Market cap$1.67B+45.7%
Enterprise value$1.64B+49.8%
P/S28×+6.4×

Profitability

See full
Operating margin-711.7%-149pp
Net margin-672.2%-139pp
FCF margin-586%-123pp

Returns & leverage

See full
Return on equity-56.3%-1.5pp
Debt / equity0.1×
Current ratio6.6×+1.5×

Where this comes from

Reported directly by Intellia Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The source filing: Intellia Therapeutics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-337952
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Other income, net:
Interest income5,7977,40211,00216,005
Change in fair value of investments, net3291,339(575)(786)
Total other income, net6,1268,74110,42715,219
Net loss$(106,634)$(101,255)$(202,865)$(215,584)
Net loss per share, basic and diluted$(0.80)$(0.98)$(1.61)$(2.08)
Weighted average shares outstanding, basic and diluted133,480103,732126,057103,617
Other comprehensive loss:

Item 1. Financial Statements

FAQ

What is Intellia Therapeutics's other income (expense)?
Intellia Therapeutics (NTLA) reported other income (expense) of $6.13M in Q2 2026.
How has Intellia Therapeutics's other income (expense) changed year-over-year?
Intellia Therapeutics's other income (expense) decreased by 29.9% year-over-year, from $8.74M to $6.13M.
What is the long-term trend for Intellia Therapeutics's other income (expense)?
Over 4 years (2021 to 2025), Intellia Therapeutics's other income (expense) has grown at a 409.5% compound annual growth rate (CAGR), from -$42K to $28.3M.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.

Ask your AI about Intellia Therapeutics's other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude